Business Context and Reporting Period
This Form 8-K, dated January 18, 2017, reports that PharmAthene, Inc. (the registrant) entered into a definitive Merger Agreement with Altimmune, Inc. The transaction involves a two-step merger where Altimmune will become a wholly-owned subsidiary of PharmAthene, and PharmAthene will subsequently change its name to Altimmune. The filing also details related financing agreements, voting agreements, lock-up provisions, and executive retention arrangements.
Key Financial Metrics and Transaction Terms
- Equity Structure: Post-merger, Altimmune shareholders will own 58.2% of the combined entity, while PharmAthene shareholders will own 41.8%.
- Financing Commitments:
- Altimmune Private Placement: Minimum $3.5 million in gross proceeds to be received prior to the Effective Time.
- Post-Closing Private Placement: Minimum $5.0 million in gross proceeds for PharmAthene to be raised within 135 days of closing.
- Escrow Arrangement: 10% of the merger consideration issuable to Altimmune stockholders will be held in escrow for 12 months to secure indemnification obligations.
- Termination Fees:
- PharmAthene may be required to pay Altimmune a termination fee of $2,000,000 under specific superior offer scenarios.
- Either party may be required to pay the other's third-party expenses up to $1,000,000 upon certain terminations.
- Executive Compensation: PharmAthene CFO Phillip MacNeill has a retention agreement providing for a potential severance of $93,094.61 and a bonus of $67,235 if he remains employed through the closing.
Material Changes and Governance
The filing outlines significant structural changes pending stockholder approval:
- Board Composition: The combined company's Board will initially consist of seven directors: four designated by Altimmune and three by PharmAthene.
- Leadership: Altimmune's CEO, Bill Enright, and CFO, Elizabeth Czerepak, are expected to serve as the CEO and CFO of the combined company, respectively.
- Stock Split: PharmAthene stockholders will be asked to approve a reverse stock split prior to the Effective Time at a ratio to be mutually agreed upon.
- Legal Forum: PharmAthene amended its Bylaws to designate the Court of Chancery in Delaware as the exclusive forum for specified corporate actions.
Outlook, Risks, and Contingencies
The transaction is subject to several conditions, including stockholder approval from both companies and the delivery of Voting Agreements from holders of at least 65% of Altimmune's Class A Common Stock. Key risks identified include:
- Failure to obtain necessary stockholder approvals.
- Delays in closing or failure to complete the transaction.
- Operational disruptions and challenges in integrating the two businesses.
- Reliability of clinical study results and potential adverse effects of product candidates.
- Unexpected funding delays or reductions in U.S. government funding for development programs.
The filing notes that the final joint proxy statement/prospectus will contain more detailed information and risks.
Investor Verification Checklist
- Verify the final Exchange Ratio and the specific reverse stock split ratio once approved by the Boards.
- Confirm the successful closing of the $3.5 million Altimmune Private Placement prior to the Effective Time.
- Monitor the status of Voting Agreements from Altimmune stockholders (65% threshold required).
- Review the upcoming Joint Proxy Statement/Prospectus (Form S-4) for detailed risk factors and financial projections.
- Track the 180-day lock-up period expiration for Altimmune and PharmAthene insiders post-closing.